Amgen

Results: 561



#Item
381Microsoft Word - EPO Letter Final[removed]doc

Microsoft Word - EPO Letter Final[removed]doc

Add to Reading List

Source URL: www.amgen.com

Language: English - Date: 2013-10-01 12:19:56
382Microsoft Word - SNF Round 2 Faxblast[removed]DRAFTv3.doc

Microsoft Word - SNF Round 2 Faxblast[removed]DRAFTv3.doc

Add to Reading List

Source URL: www.amgen.com

Language: English - Date: 2013-10-01 12:20:21
383Certificate of Separation Amgen is committed to complying with Independent Medical Education (“IME”) accreditation requirements that IME content remain separate and independent from undue influence of the commercial

Certificate of Separation Amgen is committed to complying with Independent Medical Education (“IME”) accreditation requirements that IME content remain separate and independent from undue influence of the commercial

Add to Reading List

Source URL: www.amgen.com

Language: English - Date: 2014-01-03 14:08:26
384Microsoft Word - Form A - Sponsor Enrollment Form-blankv2[removed]doc

Microsoft Word - Form A - Sponsor Enrollment Form-blankv2[removed]doc

Add to Reading List

Source URL: www.amgen.com

Language: English - Date: 2013-10-01 12:19:59
385MEDICATION GUIDE PROCRIT® (PROKRIT) (epoetin alfa) Read this Medication Guide:  before you start PROCRIT.  if you are told by your healthcare provider that there is new information about PROCRIT.

MEDICATION GUIDE PROCRIT® (PROKRIT) (epoetin alfa) Read this Medication Guide:  before you start PROCRIT.  if you are told by your healthcare provider that there is new information about PROCRIT.

Add to Reading List

Source URL: www.procrit.com

Language: English - Date: 2014-01-07 15:29:47
386Non-Cash Donation Form Date last updated: [removed]Qualifications: This program is currently applicable to North America and Puerto Rico only; Health Care Providers are not eligible to participate in the program.

Non-Cash Donation Form Date last updated: [removed]Qualifications: This program is currently applicable to North America and Puerto Rico only; Health Care Providers are not eligible to participate in the program.

Add to Reading List

Source URL: www.amgen.com

Language: English - Date: 2013-10-01 12:19:16
387NEUPOGEN® (filgrastim) DESCRIPTION Filgrastim is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by ® recombinant DNA technology. NEUPOGEN is the Amgen Inc. trademark for filgrastim‚ which has been

NEUPOGEN® (filgrastim) DESCRIPTION Filgrastim is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by ® recombinant DNA technology. NEUPOGEN is the Amgen Inc. trademark for filgrastim‚ which has been

Add to Reading List

Source URL: patentdocs.typepad.com

Language: English - Date: 2014-07-29 01:16:49
388Microsoft Word - DLPReview.doc

Microsoft Word - DLPReview.doc

Add to Reading List

Source URL: www.ipo.gov.uk

Language: English - Date: 2009-01-05 07:26:46
389Patent Inter-Partes Decision O[removed]

Patent Inter-Partes Decision O[removed]

Add to Reading List

Source URL: www.ipo.gov.uk

Language: English - Date: 2007-07-09 09:18:30
390Microsoft Word - Form A - Sponsor Enrollment Form-blankv2[removed]_2_.doc

Microsoft Word - Form A - Sponsor Enrollment Form-blankv2[removed]_2_.doc

Add to Reading List

Source URL: www.amgen.com

Language: English - Date: 2013-10-01 12:20:20